Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy

被引:43
作者
Kelley, ST
Coppola, D
Karl, RC
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Surg, Tampa, FL 33612 USA
[3] Univ S Florida, Dept Pathol, Tampa, FL 33612 USA
关键词
esophageal cancer; neoadjuvant therapy; complications;
D O I
10.1016/j.gassur.2003.11.024
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Recent studies have claimed a higher rate of perioperative complications related to the use of neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. We tested the hypothesis that neoadjuvant chemoradiotherapy has no significant effect on the perioperative complication rate. Data on 155 patients with esophageal carcinoma treated between 1996 and 2001 were collected in a prospective database. This included 61 patients (40%) treated with neoadjuvant chemoradiotherapy (group I) and 94 patients (60%) who underwent esophagectomy alone (group II). Neoadjuvant therapy consisted of two courses of cisplatinum and continuous-infusion 5-fluorouracil with radiation followed by esophagectomy. Ivor-Lewis esophagectomy was performed in 146 (94%) and a transhiatal resection in nine (6%). The two groups (I vs. II) were comparable in terms of age (61.3 +/- 11 years vs. 64.8 +/- 11 years), diagnosis (adenocarcinoma: 82% vs. 83%; squamous cell carcinoma:11% vs. 16%), and stage (stage 0 to I: 39% vs. 38%; stage II: 25% vs. 34%; stage III: 30% vs. 24%; and stage IV: 6% vs. 4%). The neoadjuvant group had 23 complete responses, 11 partial responses, and 27 nonresponses. There were 39 complications (25.1%) for the cohort, which included three deaths (1.9%) and four anastomotic leaks (2.6%) demonstrated by Gastrografin swallow 1 in group I vs. 3 in group II. Only one leak required reoperation (group 11); all others responded to conservative treatment. Group 1 had 14 complications (22.9%) vs. 25 (26.5%) in group II (P = NS). Groups were comparable with respect to the rate of pulmonary events (4.9% vs. 6.3%), arrhythmias (6.5% vs. 8.5%), and stricture formation (6.5% vs. 7.4%). Neoadjuvant chemoradiotherapy in patients with esophageal cancer was not associated with increased perioperative morbidity or mortality. Complete response to chemoradiotherapy also did not affect the complication rate (26% vs. 22%). (C) 2004 The Society for Surgery of the Alimentary Tract.
引用
收藏
页码:227 / 231
页数:5
相关论文
共 13 条
[1]  
*AM JOINT COMM CAN, 1992, MAN STAG CANC, P91
[2]  
Ancona E, 2001, CANCER, V91, P2165, DOI 10.1002/1097-0142(20010601)91:11<2165::AID-CNCR1245>3.3.CO
[3]  
2-8
[4]  
Bancewicz J, 2002, LANCET, V359, P1727
[5]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[6]   MULTIMODAL TREATMENT FOR SQUAMOUS-CELL ESOPHAGEAL CANCER [J].
FINK, U ;
STEIN, HJ ;
WILKE, H ;
RODER, JD ;
SIEWERT, JR .
WORLD JOURNAL OF SURGERY, 1995, 19 (02) :198-204
[7]   Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy [J].
Heidecke, CD ;
Weighardt, H ;
Feith, M ;
Fink, U ;
Zimmermann, F ;
Stein, HJ ;
Siewert, JR ;
Holzmann, B .
SURGERY, 2002, 132 (03) :495-501
[8]  
Keller SM, 1998, CANCER, V83, P1908, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1908::AID-CNCR5>3.0.CO
[9]  
2-6
[10]   Treatment of esophageal carcinoma [J].
Lerut, T ;
Coosemans, W ;
De Leyn, P ;
Van Raemdonck, D ;
Deneffe, G ;
Decker, G .
CHEST, 1999, 116 (06) :463S-465S